RATIONALE: A subgroup of atopic dermatitis patients exhibit increased susceptibility to episodes of eczema herpeticum (ADEH + ). We sought to characterize the molecular pathology of ADEH disease in non-lesional skin through whole transcriptome analysis. METHODS: Non-lesional skin biopsies were collected from non-atopic controls (NA, n513) and AD patients with (ADEH + , n515) and without (ADEH -, n513) a history of recurrent EH episodes. Biopsies were separated into dermal and epidermal layers followed by RNA extraction and whole transcriptome sequencing. Differential expression analyses were performed on the combined set of epidermal and dermal data. RESULTS: Differential expression of ADEH + vs. NA subjects yielded 174 differentially expressed genes (DEGs). Amongst the DEGs upregulated in ADEH + individuals were several biomarkers of type 2 inflammation (CCL17, CCL22, TSLP receptor sub-units IL7R and CRLF2), innate immunity (5 S100-type genes) and barrier function (3 LCE3 and 2 SPRR2). Principle component analysis (PCA) of these samples using the 174 DEGs yielded an inflammatory summary metric (PC2, 8% of variance explained) that was increased in ADEH -compared to NA subjects, but highest in the ADEH + group. This group trend in the ADEH + summary metric was also observed in both the dermal and epidermal datasets when analyzed separately. We found 543 DEGs when comparing expression between ADEH + vs (NA and ADEH -) groups. Among these were novel upregulated genes such as gasdermin C (GSDMC) and TRIM15, and genes characteristic of increased interferon signaling. CONCLUSIONS: ADEH+ subjects represent a more severe AD endotypic group characterized by higher type 2 inflammation, interferon signaling, and barrier defects in uninvolved skin.
Expression profiling of atopic dermatitis patients with a history of recurrent eczema herpeticum reveals dysregulation of type 2-inflammation and barrier-related pathways in uninvolved skin Nathan T. Dyjack, BS, Elena Goleva, PhD, Cydney Rios, MS, Michael T. Montgomery, BS, Brittany N. Richers, BS, Kathryn A. Norquest, MS, Donald Y. M. Leung, MD, PhD, FAAAAI, and Max A. Seibold, PhD; National Jewish Health, Denver, CO. RATIONALE: A subgroup of atopic dermatitis patients exhibit increased susceptibility to episodes of eczema herpeticum (ADEH + ). We sought to characterize the molecular pathology of ADEH disease in non-lesional skin through whole transcriptome analysis. METHODS: Non-lesional skin biopsies were collected from non-atopic controls (NA, n513) and AD patients with (ADEH + , n515) and without (ADEH -, n513) a history of recurrent EH episodes. Biopsies were separated into dermal and epidermal layers followed by RNA extraction and whole transcriptome sequencing. Differential expression analyses were performed on the combined set of epidermal and dermal data. RESULTS: Differential expression of ADEH + vs. NA subjects yielded 174 differentially expressed genes (DEGs). Amongst the DEGs upregulated in ADEH + individuals were several biomarkers of type 2 inflammation (CCL17, CCL22, TSLP receptor sub-units IL7R and CRLF2), innate immunity (5 S100-type genes) and barrier function (3 LCE3 and 2 SPRR2). Principle component analysis (PCA) of these samples using the 174 DEGs yielded an inflammatory summary metric (PC2, 8% of variance explained) that was increased in ADEH -compared to NA subjects, but highest in the ADEH + group. This group trend in the ADEH + summary metric was also observed in both the dermal and epidermal datasets when analyzed separately. We found 543 DEGs when comparing expression between ADEH + vs (NA and ADEH -) groups. Among these were novel upregulated genes such as gasdermin C (GSDMC) and TRIM15, and genes characteristic of increased interferon signaling. CONCLUSIONS: ADEH+ subjects represent a more severe AD endotypic group characterized by higher type 2 inflammation, interferon signaling, and barrier defects in uninvolved skin. George Washington University School of Medicine, Washington, DC. RATIONALE: The A-896G polymorphism of TLR-4 can be associated with atopic diseases with some patients with AG genotypes having high levels of total IgE. METHODS: The A-896G polymorphism of the TLR-4 gene was studied in 96 patients with atopic dermatitis. The control group included 90 nonatopic subjects. The single nucleotide polymorphism A-896G was detected by PCR. The levels of total IgE and TNF-a, IL-2, g-IF, IL-4, IL-5, IL-10, TGF-b cytokines in blood were detected by ELISA. Patients and volunteers provided written informed consent for the genetic study. RESULTS: 34 patients had extrinsic and 62 had intrinsic atopic dermatitis. In the control group, the frequency distribution of genotypes (AA -71 (78.9%), AG -18 (20.0%), GG -1 (1.1%)) was significantly different (x2 5 7.46, p 5 0.024) from those with atopic dermatitis (AA -58 (60.4%), AG -36 (37.5%), GG -2 (2.1%)). The risk of atopic dermatitis in the Ukrainian population is significantly elevated (OR 5 2.448, P 5 0.006) in the presence of the allele G. When patients were stratified for extrinsic and intrinsic atopic dermatitis increased risk of development of atopic dermatitis was associated only with the extrinsic form. In patients with intrinsic atopic dermatitis, serum IL-5 levels in the AG + GG genotype were significantly greater compared with the AA genotype. CONCLUSIONS: The risk of atopic dermatitis development is increased by the presence of the allele G of the polymorphic region A-896G of the TLR-4 gene. Children's National Medical Center, Washington, DC, 4 Children's National Health System, Washington, DC. RATIONALE: There is mixed evidence on whether breastfeeding is a protective factor for the development of eczema; furthermore, the impact of breastfeeding exclusivity remains unclear. The purpose of this study was to examine the association of exclusive breastfeeding with reported eczema diagnosis and active eczema in childhood. METHODS: Survey data from the Infant Feeding Practices Study II and its Year 6 Follow-Up were analyzed. Multivariable logistic regression models controlling for sociodemographic variables and familial history of allergic disease were used to examine associations of maternal reports of exclusive breastfeeding duration with reports at follow-up of ever being diagnosed with eczema and current symptoms of eczema among 6-yearolds (N51520). RESULTS: Prevalence of any eczema diagnosis ever was 20.33% (n5309). Among those with a previous diagnosis, prevalence of current eczema at 6 years old was 58.58% (n5181). Higher socioeconomic status (> _185% federal poverty level) and family history of food allergies were significantly associated with higher odds of ever and current eczema diagnosis. Exclusive breastfeeding duration was not significantly associated with general eczema diagnosis; however, children exclusively breastfed for > _ 3 months had significantly lower odds of continued eczema at 6 year follow-up (aOR50.477 [95%CI 0.259, 0.878], p50.017) as compared to those who were not breastfed or breastfed 0-3 months. CONCLUSIONS: Exclusive breastfeeding may not prevent eczema or eczema diagnosis, but may play a protective role in decreasing the chronicity of eczema in childhood. Future work should explore how maternal diet while breastfeeding further impacts this relationship and whether this protection continues throughout adolescence.
